Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism.
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
12
2019
revised:
10
02
2020
accepted:
23
03
2020
pubmed:
11
4
2020
medline:
12
11
2020
entrez:
11
4
2020
Statut:
ppublish
Résumé
Parkinson's disease is characterised neuropathologically by α-synuclein aggregation. Currently, there is no blood test to predict the underlying pathology or distinguish Parkinson's from atypical parkinsonian syndromes. We assessed the clinical utility of serum neuronal exosomes as biomarkers across the spectrum of Parkinson's disease, multiple system atrophy and other proteinopathies. We performed a cross-sectional study of 664 serum samples from the Oxford, Kiel and Brescia cohorts consisting of individuals with rapid eye movement sleep behavioural disorder, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome and controls. Longitudinal samples were analysed from Parkinson's and control individuals. We developed poly(carboxybetaine-methacrylate) coated beads to isolate L1 cell adhesion molecule (L1CAM)-positive extracellular vesicles with characteristics of exosomes and used mass spectrometry or multiplexed electrochemiluminescence to measure exosomal proteins. Mean neuron-derived exosomal α-synuclein was increased by twofold in prodromal and clinical Parkinson's disease when compared with multiple system atrophy, controls or other neurodegenerative diseases. With 314 subjects in the training group and 105 in the validation group, exosomal α-synuclein exhibited a consistent performance (AUC=0.86) in separating clinical Parkinson's disease from controls across populations. Exosomal clusterin was elevated in subjects with non-α-synuclein proteinopathies. Combined neuron-derived exosomal α-synuclein and clusterin measurement predicted Parkinson's disease from other proteinopathies with AUC=0.98 and from multiple system atrophy with AUC=0.94. Longitudinal sample analysis showed that exosomal α-synuclein remains stably elevated with Parkinson's disease progression. Increased α-synuclein egress in serum neuronal exosomes precedes the diagnosis of Parkinson's disease, persists with disease progression and in combination with clusterin predicts and differentiates Parkinson's disease from atypical parkinsonism.
Identifiants
pubmed: 32273329
pii: jnnp-2019-322588
doi: 10.1136/jnnp-2019-322588
pmc: PMC7361010
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
720-729Subventions
Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M024962/1
Pays : United Kingdom
Organisme : Parkinson's UK
ID : J-0901
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/N50192X/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: HW and JR are employees of Eli Lilly and Company.
Références
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Lancet Neurol. 2011 Mar;10(3):230-40
pubmed: 21317042
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Brain. 2009 Dec;132(Pt 12):3298-307
pubmed: 19843648
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Sci Transl Med. 2012 Feb 15;4(121):121ra20
pubmed: 22344688
Neurobiol Aging. 2010 Jan;31(1):99-103
pubmed: 18457903
Parkinsonism Relat Disord. 2014 Jan;20(1):99-105
pubmed: 24183678
Mov Disord. 2012 Sep 15;27(11):1364-9
pubmed: 22927213
Transl Neurodegener. 2019 Apr 3;8:11
pubmed: 30984390
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):E4688-97
pubmed: 27444016
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Metab Brain Dis. 2019 Feb;34(1):129-140
pubmed: 30291488
Neurobiol Dis. 2011 Jun;42(3):360-7
pubmed: 21303699
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):852-6
pubmed: 12810766
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Nat Genet. 2009 Oct;41(10):1088-93
pubmed: 19734902
Neurosci Lett. 2010 Aug 9;480(1):78-82
pubmed: 20540987
Neurobiol Aging. 2020 May;89:129-131
pubmed: 31813628
Cell Mol Life Sci. 2007 Sep;64(17):2194-201
pubmed: 17605001
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
PLoS One. 2011;6(12):e29460
pubmed: 22216284
Neurobiol Aging. 2015 Nov;36(11):3108-3115
pubmed: 26329689
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17004-9
pubmed: 21953697
Cell Death Dis. 2018 Jul 9;9(7):757
pubmed: 29988147
Ann Clin Transl Neurol. 2015 Apr;2(4):353-61
pubmed: 25909081
FASEB J. 2003 Oct;17(13):1945-7
pubmed: 14519670
Brain. 2018 Jul 1;141(7):2181-2193
pubmed: 29878075
Ann Neurol. 2012 Jan;71(1):49-56
pubmed: 22275251
FASEB J. 2015 Feb;29(2):589-96
pubmed: 25342129
Neurology. 2010 Nov 9;75(19):1717-25
pubmed: 21060094
Front Cell Neurosci. 2018 May 18;12:125
pubmed: 29867358
Acta Neuropathol. 2008 Apr;115(4):399-407
pubmed: 18297293
Neurology. 2015 Mar 17;84(11):1104-13
pubmed: 25681454
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Acta Neuropathol Commun. 2017 Nov 7;5(1):81
pubmed: 29115989
J Parkinsons Dis. 2017;7(4):569-576
pubmed: 28922170
Neurobiol Aging. 2019 Jul;79:101-109
pubmed: 31029938
Acta Neuropathol. 2014 Nov;128(5):639-650
pubmed: 24997849
Alzheimers Dement. 2015 Jun;11(6):600-7.e1
pubmed: 25130657
Nat Genet. 2009 Oct;41(10):1094-9
pubmed: 19734903
Mov Disord. 2017 Oct;32(10):1389-1400
pubmed: 28880418